Gambogic acid and chloroquine synergistically induce cell death via increasing mitochondria damage in human NSCLC cells

Abstract

Gambogic acid is a natural bioactive compound from the brownish resin of the Garcinia hanburyi trees, which has been shown to induce cell death of cancer cells with a synergistic effect together with other compounds. In the present study, we aim to investigate whether the combination of gambogic and chloroquine, one of the inhibitor of autophagy, could increase cell death in human NSCLC cells. As a result, gambogic acid and chloroquine synergistically suppress the growth of NSCLC cells (CI <0.9). Moreover, the combination of gambogic acid and chloroquine significantly promotes apoptosis than that either alone does. Mechanistically, the results demonstrate that gambogic acid increases PINK1 expression at mRNA and protein level, accompanied with downregulation of Tom20, suggesting the mitophagy process is activated. Both silencing PINK1 and treatment of chloroquine could inhibit mitophagy, therefore disrupting the clearance of damaged mitochondria. Thus, co-treatment of gambogic acid and chloroquine results in an elevated level of ROS, which facilitates cell death. Taken together, our finding highlights that the synergistically inhibitory effect of gambogic acid and chloroquine on NSCLC cells is associated with the accumulation of mitochondrial damage.

Keywords

apoptosis / chloroquine / gambogic acid / mitochondria / NSCLC

References

[1] LiuYL, ChenYC, LinLF, Li H. Gambogic acid as a candidate for cancer therapy: a review. Int J Nanomed. 2020; 15: 10385-10399.

[2] ChiYHBL, ZhanXK, YuH, et al. An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J. 2013; 126: 1642-1646.

[3] NunnariJ, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012; 148: 1145-1159.

[4] AshrafiG, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013; 20: 31-42.

[5] PanigrahiDP, Praharaj PP, BholCS, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020; 66: 45-58.

[6] BernardiniJP, Lazarou M, DewsonG. Parkin and mitophagy in cancer. Oncogene. 2017; 36: 1315-1327.

[7] YaoN, WangCR, HuN, et al. Inhibition of PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant cancer cells to B5G1, a new betulinic acid analog. Cell Death Dis. 2019; 10(3): 232.

[8] VillaE, ProicsE, Rubio-PatinoC. et al. Parkin-independent mitophagy controls chemotherapeutic response in cancer cells. Cell Rep. 2017; 20: 2846-2859.

[9] GuizzuntiG, BatovaA, ChantarasriwongO, DakanaliM, Theodorakis EA. Subcellular localization and activity of gambogic acid. Chembiochem. 2012; 13: 1191-1198.

[10] BronnerDN, O’Riordan MX. Measurement of mitochondrial DNA release in response to ER stress. Bio Protoc. 2016; 6(12): e1839.

[11] ZhuX, ZhangH, LinY, et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 2009; 21: 666-672.

[12] BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.

[13] ChenZ, Fillmore CM, HammermanPS, KimCF, WongKK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14: 535-546.

[14] HerbstRS, Morgensztern D, BoshoffC. The biology and management of non-small cell lung cancer. Nature. 2018; 553: 446-454.

[15] KrisMG, GasparLE, ChaftJE, et al. EAdjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update. J Clin Oncol. 2017; 35: 2960.

[16] Al-YozbakiM, WilkinPJ, GuptaGK, Wilson CM. Therapeutic potential of natural compounds in lung cancer. Curr Med Chem. 2021; 28: 7988-8002.

[17] HatamiE, JaggiM, ChauhanSC, Yallapu MM. Gambogic acid: a shining natural compound to nanomedicine for cancer therapeutics. Biochim Biophys Acta Rev Cancer. 2020; 1874(1): 188381.

[18] LiuYT, HaoK, LiuXQ, Wang GJ. Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin. 2006; 27: 1253-1258.

[19] HaoK, LiuXQ, WangGJ, Zhao XP. Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur J Drug Metab Pharmacokinet. 2007; 32: 63-68.

[20] CaiLL, QiuN, XiangML, et al. Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG(2000) micelles. Int J Nanomed. 2014; 9: 243-255.

[21] HatamiE, NageshPKB, JaggiM, Chauhan SC, YallapuMM. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol. 2020; 888: 173486.

[22] ZhangWD, ZhouHC, YuY, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Onco Targets Ther. 2016; 9: 3359-3368.

[23] WangJX, YuanZX. Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis. Cell Biochem Biophys. 2013; 67: 199-206.

[24] WangYH, SuiYN, TaoYG. Gambogic acid increases the sensitivity to paclitaxel in drug-resistant triple-negative breast cancer via the SHH signaling pathway. Mol Med Rep. 2019; 20: 4515-4522.

[25] WeiJC, YangP, LiWL, et al. Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis. Exp Ther Med. 2017; 13: 662-668.

[26] WestAP. Mitochondrial dysfunction as a trigger of innate immune responses and inflammation. Toxicology. 2017; 391: 54-63.

[27] KhandiaR, MunjalA. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020; 119: 199-245.

[28] BurkePJ. Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer. 2017; 3: 857-870.

[29] ChangJY, YiHS, KimHW, Shong M. Dysregulation of mitophagy in carcinogenesis and tumor progression. Biochim Biophys Acta Bioenerg. 2017; 1858: 633-640.

[30] DrakeLE, Springer MZ, PooleLP, KimCJ, Macleod KF. Expanding perspectives on the significance of mitophagy in cancer. Semin Cancer Biol. 2017; 47: 110-124.

[31] YamashitaK, MiyataH, MakinoT, et al. High expression of the mitophagy-related protein Pink1 is associated with a poor response to chemotherapy and a poor prognosis for patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2017; 24: 4025-4032.

[32] WuM, LuG, LaoYZ, et al. Garciesculenxanthone B induces PINK1-Parkin-mediated mitophagy and prevents ischemia-reperfusion brain injury in mice. Acta Pharmacol Sin. 2021; 42: 199-208.

[33] BockFJ, TaitSWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020; 21: 85-100.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.